Celldex Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
CLDX$31.24+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| | Page | |
|---|---|---|
| Part I — Financial Information | 3 | |
| Item 1. Unaudited Financial Statements | 3 | |
| Condensed Consolidated Balance Sheets at September 30, 2026 and December 31, 2025 | 3 | |
| Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2026 and 2025 | | 4 |
| Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025 | | 5 |
| Notes to Unaudited Condensed Consolidated Financial Statements | 6 | |
| Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 17 | |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | 39 | |
| Item 4. Controls and Procedures | 39 | |
| Part II — Other Information | 40 | |
| Item 1A. Risk Factors | 40 | |
| Item 5. Other Information | | 40 |
| Item 6. Exhibits | 40 | |
| Exhibit Index | 40 | |
| Signatures | 41 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.